

# NLCA


## Spotlight report on molecular testing in patients with advanced lung cancer

Published 2019

**60**   
**NHS trusts**

provided data on **1,157 patients** diagnosed with advanced lung cancer between June – September 2017

Median turnaround time (in days) from tissue acquisition to result



**83%** of patients with advanced adenocarcinoma had molecular testing for all three of the recommended predictive biomarkers



**11.5%** of patients required second biopsies to obtain molecular results



**96%** of molecular tests were successful in providing adequate results



**75%** of patients received first-line targeted therapies following confirmation of an *EGFR* mutation

ALK = anaplastic lymphoma kinase  
PD-L1 = programmed death ligand 1  
EGFR = epidermal growth factor receptor